Home › Learn › Who Should Not Use GLP-1 Sprays

Safety First

Who should NOT use GLP-1 maintenance sprays

Most articles about GLP-1 therapy focus on who it might help. This one is about who it isn't for. GLP-1 medications — in any format, including prescription-only compounded sublingual sprays — carry real contraindications, and an honest program tells you about them upfront. If any of the situations below apply to you, share them fully with a licensed provider before considering any GLP-1 therapy.

Pregnancy, trying to conceive, or breastfeeding

GLP-1 medications are generally not recommended during pregnancy or while breastfeeding, and providers typically advise stopping them well before a planned pregnancy. Weight loss itself is not advised during pregnancy, and there isn't adequate human data to establish safety for a developing baby or a nursing infant. If you are pregnant, planning to become pregnant, or breastfeeding, tell your provider — this is one of the clearest situations in which GLP-1 therapy is not appropriate.

Personal or family history of MTC or MEN 2

Injectable GLP-1 medications carry warnings related to thyroid C-cell tumors observed in rodent studies. Whether the same risk applies to humans is not established, but out of caution, these medications are contraindicated for people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The same caution is applied to compounded GLP-1 formulations. If thyroid cancer of any kind appears in your family history, disclose it — a provider needs that information to evaluate you safely.

Type 1 diabetes

GLP-1 receptor agonists are not a treatment for type 1 diabetes and are not a substitute for insulin. In people who require insulin, adding appetite-suppressing medication without close specialist management can also raise the risk of hypoglycemia and disordered eating patterns around insulin dosing. People with type 1 diabetes should not use GLP-1 maintenance sprays outside the direct care of their endocrinologist — and telehealth maintenance programs are generally not the right setting for that care.

Significant kidney impairment

GLP-1 medications commonly cause gastrointestinal side effects — nausea, vomiting, diarrhea — and in some reported cases the resulting dehydration has worsened kidney function. For patients who already have significant kidney impairment, that margin for error is smaller. If you have chronic kidney disease or a history of acute kidney injury, a provider needs to weigh that history carefully, and may determine that GLP-1 therapy is not appropriate for you.

Prior serious reactions to GLP-1 medications

A history of serious hypersensitivity — such as anaphylaxis or angioedema — to semaglutide, tirzepatide, or any other GLP-1 receptor agonist rules out further use of that medication. Allergic cross-reactivity within the class is possible, so disclose any prior reaction, even one that seemed mild, to any provider evaluating you.

Situations that require extra caution

Some histories don't automatically rule out therapy but demand a careful, individualized provider conversation:

• Pancreatitis history. Pancreatitis has been reported in people using GLP-1 medications; a prior episode is a significant flag.
• Gallbladder disease. Gallbladder events have been reported with GLP-1 therapy and with rapid weight loss generally.
• Diabetic retinopathy. Rapid changes in blood sugar control can temporarily affect retinopathy; monitoring matters.
• Severe gastrointestinal disease. Conditions like gastroparesis can be aggravated by medications that slow stomach emptying.
• History of an eating disorder. Appetite-suppressing medication deserves careful, honest discussion with a provider who knows this history.

Why full disclosure protects you

Every safeguard above depends on one thing: the provider knowing your real history. An intake form only works if it's answered honestly — including the family history questions, the medication list, and the conditions you might consider minor or long resolved. Prescription-only compounded sprays like THIN™ are not FDA-approved and are dispensed only if a licensed provider determines they are appropriate; that determination is only as good as the information you provide. If you're unsure whether something in your history matters, include it anyway and let the provider decide. Our 60-second eligibility check covers the major screening questions, and a licensed provider reviews every intake before anything is prescribed — or declined.

Being told "this isn't right for you" is not a failure of the process. It's the process doing exactly what it should.